Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
ANNX Stock Chart & Stats
$5.63
-$0.26(-5.25%)
At close: 4:00 PM EST
$5.63
-$0.26(-5.25%)
Day’s Range― - ―
52-Week Range$1.29 - $7.18
Previous CloseN/A
Volume252.73K
Average Volume (3M)2.27M
Market Cap
$814.82M
Enterprise Value$560.67M
Total Cash (Recent Filing)$188.72M
Total Debt (Recent Filing)$26.94M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 09, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding144,728,960
10 Day Avg. Volume2,037,452
30 Day Avg. Volume2,273,054
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio-5.97
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-614.77
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$17.00Price Target Upside201.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial RunwayA cash balance of about $188.7 million and extended cash guidance into the first quarter of 2027 provide funding to support upcoming readouts and regulatory activities, reducing near-term financing risk.
Pipeline PositioningTwo late-stage, first-in-class complement inhibitors targeting the classical pathway offer differentiated therapeutic potential, and tanruprubart could become the new standard of care for Guillain-Barré syndrome given the lack of approved therapies.
Regulatory ProgressEMA selection of vonaprument for the PRIME pilot, harmonization of BCVA endpoints across U.S. and EU, and a tanruprubart MAA filing on track for January 2026 collectively lower approval risk for lead programs.
Bears Say
Clinical Timeline RiskProof-of-concept data for the oral C1s candidate ANX1502 has been delayed into 2026, extending development uncertainty for the oral program and deferring a potential value catalyst.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $1.28 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $814.82M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is Mar 09, 2026 which is in 25 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Nov 10, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.341 by -$0.029.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -0.32.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 144,728,960 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.341. Following the earnings report the stock price went down -0.336%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (201.95% Upside)
$17.00 (201.95% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $8.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.66%
12-Months-Change
Fundamentals
Return on Equity
-83.98%
Trailing 12-Months
Asset Growth
-39.50%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$17.00
▲(201.95% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.42% Insiders
12.88% Mutual Funds
0.01% Other Institutional Investors
68.25% Public Companies and
Individual Investors